POLYAMINE-MODULATED HISTONE ACETYLATION IN TUMORIGENESIS

肿瘤发生中多胺调节的组蛋白乙酰化

基本信息

项目摘要

DESCRIPTION: (provided by applicant) Omithine decarboxylase (ODC) is a key regulatory enzyme in the biosynthesis of polyamines which are essential for normal cell growth and differentiation. Although ODC overexpression is not sufficient to induce tumors in normal cells, we have demonstrated that elevated levels of ODC and polyamines cooperate with activated Ha-ras to promote epithelial tumor formation and invasion. Due to their cationic nature, polyamines have been suspected to affect overall chromosome conformation, thereby contributing to transcriptional regulation. Recently it has been shown that histone acetyltransferase (HAT) and deacetylase (HDAC) activities intrinsic to some transcriptional control proteins are targeted to various gene promoters causing dynamic remodeling of chromatin and leading to the activation or repression of transcription. Elevated levels of ODC and polyamines alter the expression of a number of genes that are associated with proliferation and differentiation. Significantly, we have found that they also promote changes in histone acetylation which can be reversed with the specific ODC inhibitor, alpha-difluoromethylomithine. The overall goal of this project is to determine how polyamines mediate changes in the chromatin environment, and the consequences for gene expression in the context of epithelial tumorgenesis. Thus, we propose the following specific aims: 1. To establish a link between polyamine induced alterations in histone acetylation and transcriptional activity of impacted genes which are key to malignant transformation of epidermal cells by: a. identifying specific genes that are transcriptionally regulated by polyamines using representative difference analysis (RDA) of transcriptionally competent genomic DNA purified by chromatin immunoprecipitation (ChIP) or mercury affinity chromatography, and b. verifying altered acetylation of nucleosomes associated with promoters of genes transcriptionally regulated by polyamines in cells or tissue expressing high versus normal levels of ODC. 2. To identify the mechanism(s) by which polyamines modulate the function of HATs and HDACs in the skin. Using reporter gene-based strategies, we will: 1) determine the role of HAT/HDAC enzymatic activities in mediating polyamine effects on reporter gene transactivation or repression, and 2) examine the effect of elevated levels of polyamines on the interactions between various protein components of chromatin remodeling complexes that are involved in targeting HATs and HDACs to specific gene promoters. We will also begin to characterize/identify the HAT(s) responsible for the aberrantly high HAT activity observed in tumors from ODC/Ras double transgenic mice. 3.To elucidate the individual mechanism(s) by which polyamines modulate the remodeling of chromatin at promoters of specific genes that are differentially acetylated and whose expression is correspondingly altered in response to ODC overexpression.
描述:(申请人提供)欧米氨酸脱羧酶(ODC)是一个关键 调节酶在多胺的生物合成中是必不可少的 正常的细胞生长和分化。尽管ODC过度表达不是 足以在正常细胞中诱发肿瘤,我们已经证明 ODC和多胺水平与激活的Ha-ras协同促进 上皮性肿瘤的形成和侵袭。由于它们的阳离子性质, 多胺被怀疑会影响染色体的整体构象, 从而有助于转录调控。最近,它被展示出来了 组蛋白乙酰转移酶(HAT)和脱乙酰酶(HDAC)活性 一些转录控制蛋白的固有作用于不同的基因。 导致染色质动态重塑并导致激活的启动子 或对转录的抑制。ODC和多胺水平的升高会改变 一些与增殖相关的基因的表达和 差异化。值得注意的是,我们发现它们还促进了 组蛋白乙酰化,可以用特定的ODC抑制剂逆转, α-二氟甲亚胺。这个项目的总体目标是确定 多胺如何调节染色质环境的变化,以及 上皮性肿瘤发生背景下基因表达的后果。 为此,我们提出了以下具体目标:1.建立 多胺诱导组蛋白乙酰化和转录的改变 受影响基因的活性,这些基因是恶性转化的关键 通过:A.鉴定转录水平上的特定基因 多胺调控的代表性差异分析(RDA) 染色质纯化具有转录活性的基因组DNA 免疫沉淀(CHIP)或汞亲和层析;B.验证 与基因启动子相关的核小体乙酰化改变 在高表达细胞或组织中受多胺的转录调控 与正常的ODC水平相比。2.明确机制(S) 多胺调节皮肤中HATS和HDAC的功能。使用记者 基于基因的策略,我们将:1)确定HAT/HDAC酶的作用 多胺对报告基因反式激活的调节作用 抑制,以及2)检查多胺水平升高对 染色质重塑不同蛋白质组分之间的相互作用 参与靶向特定基因的HATS和HDAC的复合体 推动者。我们还将开始表征/确定负有责任的帽子(S) 在ODC/RAS双重来源的肿瘤中观察到异常高的HAT活性 转基因小鼠。3.阐明多胺的个体机制(S) 在特定基因的启动子上调节染色质的重塑 差异乙酰化,其表达相应地改变在 对ODC过度表达的响应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susan K. Gilmour其他文献

Late Breaking Abstracts for the 31<sup>st</sup> European Society for Dermatological Research (ESDR) Meeting 2001 Stockholm, Sweden September, 20–22, 2001
  • DOI:
    10.1046/j.1523-1747.2001.1170061677.x
  • 发表时间:
    2001-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Susan K. Gilmour;Kimberly A. Teti;Kai Q. Wu;Rebecca J. Morris
  • 通讯作者:
    Rebecca J. Morris

Susan K. Gilmour的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susan K. Gilmour', 18)}}的其他基金

Age-related changes in stromal cancer modifier genes
间质癌修饰基因与年龄相关的变化
  • 批准号:
    6970110
  • 财政年份:
    2005
  • 资助金额:
    $ 30.04万
  • 项目类别:
Age-related changes in stromal cancer modifier genes
间质癌修饰基因与年龄相关的变化
  • 批准号:
    7140498
  • 财政年份:
    2005
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINE-MODULATED HISTONE ACETYLATION IN TUMORIGENESIS
肿瘤发生中多胺调节的组蛋白乙酰化
  • 批准号:
    6875795
  • 财政年份:
    2002
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINE-MODULATED HISTONE ACETYLATION IN TUMORIGENESIS
肿瘤发生中多胺调节的组蛋白乙酰化
  • 批准号:
    7030345
  • 财政年份:
    2002
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINE-MODULATED HISTONE ACETYLATION IN TUMORIGENESIS
肿瘤发生中多胺调节的组蛋白乙酰化
  • 批准号:
    6465337
  • 财政年份:
    2002
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINE-MODULATED HISTONE ACETYLATION IN TUMORIGENESIS
肿瘤发生中多胺调节的组蛋白乙酰化
  • 批准号:
    6623395
  • 财政年份:
    2002
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINES AND EPITHELIAL TUMORIGENESIS
多胺与上皮肿瘤发生
  • 批准号:
    6646451
  • 财政年份:
    2000
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINES AND EPITHELIAL TUMORIGENESIS
多胺与上皮肿瘤发生
  • 批准号:
    6376251
  • 财政年份:
    2000
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINES AND EPITHELIAL TUMORIGENESIS
多胺与上皮肿瘤发生
  • 批准号:
    6759479
  • 财政年份:
    2000
  • 资助金额:
    $ 30.04万
  • 项目类别:
POLYAMINES AND EPITHELIAL TUMORIGENESIS
多胺与上皮肿瘤发生
  • 批准号:
    6194035
  • 财政年份:
    2000
  • 资助金额:
    $ 30.04万
  • 项目类别:

相似海外基金

The transcriptional control of vascular calcification in disease
疾病中血管钙化的转录控制
  • 批准号:
    10647475
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Oxidative Lipidomics in Pediatric Traumatic Brain Injury
氧化脂质组学在小儿创伤性脑损伤中的应用
  • 批准号:
    10844023
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Cellular mechanisms of NLRP3 activation by ALCAT1 in diet-induced obesity
饮食诱导肥胖中 ALCAT1 激活 NLRP3 的细胞机制
  • 批准号:
    10658507
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
  • 批准号:
    10589484
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Redefining the factors that determine tear film stability to develop novel therapeutics for evaporative dry eye disease
重新定义决定泪膜稳定性的因素,开发蒸发性干眼病的新疗法
  • 批准号:
    10678045
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Recombinant production of structured fats that mimic human milk fat
重组生产模仿人乳脂肪的结构脂肪
  • 批准号:
    10822765
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Triggering a New Cancer Cell Death Mechanism in Sarcoma
触发肉瘤中新的癌细胞死亡机制
  • 批准号:
    10735740
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
The Function of Mammalian LPGAT1
哺乳动物LPGAT1的功能
  • 批准号:
    10563280
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Enzymology of Bacteroides short and branched chain fatty acid metabolism
拟杆菌短链和支链脂肪酸代谢的酶学
  • 批准号:
    10651505
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 30.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了